Curaleaf International to Present Positive Clinical and Pre-Clincial Research
Retrieved on:
Thursday, October 20, 2022
Research, Finance, Cannabis, Clinical Trials, Professional Services, Alternative Medicine, Health, Science, Natural Resources, News, International, Dyspareunia, Imperial College London, University of Insubria, Migraine, Cannabis, Inflammation, Growth, Conference, Woman, Science, Curaleaf, Brain-derived neurotrophic factor, Genital wart, Patient, Grassroots, Lists of diseases, Research, VBD, BDNF, CNSX, International Medical School, University of Milan, University, Sex, Trial of the century, Company, Vulval vestibule, MPFC, ROS, CSE, Pain, Canadian Securities Exchange, Karger Publishers, OTCQX, ECS, Plasma, PMN, Brain, Reactive oxygen species, Title, Pharmaceutical industry, Drug, Audit, CBD, Cannabinoid, Select, Cannabidiol
MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.
Key Points:
- MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.
- For further information on the preclinical research to be presented, please see the footnote at the end of this announcement.
- Curaleaf International (formerly EMMAC Life Sciences Group) is Europes largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production.
- Curaleaf International assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.